title: [Risk of gastrointestinal bleeding with aspirin and platelet antiaggregants].
abstract: Aspirin is widely used for the prevention of thrombotic cardiovascular disease. The effect of platelet antiaggregation is achieved with low doses of 75-325 mg/day. Due to COX-1 inhibition, associated gastrointestinal adverse effects can occur. Other drugs whose platelet antiaggregant effect is achieved through different mechanisms of action have been developed, such as clopidogrel and ticlopidine, which do not inhibit COX-1. The proportion of patients taking low-dose aspirin alone or in combination with other antiaggregants is high and consequently the use of these drugs should be optimized by reducing their gastrointestinal adverse effects to a minimum. Knowledge of the risk factors that increase the risk of gastrointestinal adverse effects with platelet antiaggregants, such as age, concomitant use of other drugs such as anticoagulants or non-steroidal anti-inflammatory drugs, a history of peptic ulcer -whether complicated or uncomplicated-, and Helicobacter pylori infection, would help to allow management to be individually tailored to each patient. The use of proton pump inhibitors and/or H. pylori eradication should allow a positive balance, even in patients with gastrointestinal risk factors.
authors.affiliation: Instituto Aragonés de Ciencias de la Salud, Servicio de Aparato Digestivo, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Nardulli
authors.forename: Angel
authors.initials: A
authors.lastname: Lanas
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D000077144:Clopidogrel; D051545:Cyclooxygenase 1 / Q000187:drug effects; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D015232:Dinoprostone / Q000502:physiology; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced*; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy; D016480:Helicobacter pylori / Q000187:drug effects; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D016595:Misoprostol / Q000627:therapeutic use; D010438:Peptic Ulcer Hemorrhage / Q000139:chemically induced / Q000209:etiology; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D013931:Thromboxanes / Q000037:antagonists & inhibitors; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000925:Anticoagulants; D016861:Cyclooxygenase Inhibitors; D006635:Histamine H2 Antagonists; D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D013931:Thromboxanes; D016595:Misoprostol; D000077144:Clopidogrel; D051545:Cyclooxygenase 1; D015232:Dinoprostone; D013988:Ticlopidine; D001241:Aspirin